Automatic processes to link everything in a typical MacDonald’s branch

Automatic processes to link everything in a typical MacDonald’s branch

1) POS System
It is possible to create applications to report sales and accounting automatically where there is an option to do time reporting 3 times a day  to the management or to login via Internet to do any tasks. Accounting processes can also be automated to create views so that if the management so wishes, a report can easily be generated within minutes, creating business intelligence to give insight to any branch.
2) Linking To McDelivery 
Whatever can be done on a POS system can easily be extended to McDelivery.
3) Using RF technology for automated order and stocktaking
Stocks can be updated in real time with a simple terminal like an iPad, where it is even possible to know everything in a cold store, a substation like a frying station or just plain packaging for all McDonald’s products. Once stocks run low, an application can easily be customised to make a new order from suppliers, it is possible then to use GPS location to find anything in a store in the main warehouse, so that supplies can easily be controlled, manufactured and delivered.
4) Temperature monitoring and control of kitchen appliances via Zwave Technology
Zwave technology uses a network mesh where it is possible to link every kitchen appliances to monitor temperature, conditions or completion of any processes. Once maintenance is required it could easily sent a message to the head office to dispatch the maintenance crew. As I mentioned earlier, diversification in this area of business could easily generate new revenues where it is possible to get up to 3X more revenue than the present business model where you can maximise labour productivity with less unskilled crew, creating mass value for franchise owners. Therefore with control over every reporting tools, management could easily give directions to franchise owners to get the maximum ROI for every branch in MacDonald’s network, where it is possible to increase the new number of franchisees by another 50% worldwide. Even the spinoff of McCafe could be easily generated by creating interest from investors by studying the appropriate products that is required for each local branch, the markets is big enough if you do not have destructive competition directly with StarBucks, Coffee Beans and other competition.

My main objective is to create jobs for everyone and I do not expect anything in return.
– Contributed by Oogle.

There is no danger the amoeba, Naegleria Fowleri, will spread thru the contamination of water becos it only survive in warm water, just boil your water before using

A rare brain-eating amoeba is responsible for at least 10 deaths in the Pakistani city of Karachi in recent months, health officials believe.

The source of the parasite is not yet known, but it is thought victims may have been exposed to it when using water to rinse their nasal passages.
The amoeba, Naegleria Fowleri, lives in warm water and kills its victims by destroying brain tissue.
Officials are now increasing the amount of chlorine in the public water supply.
The deaths are in various locations across Karachi, Pakistan’s biggest city.
Dr Shakeel Mallick, who works for the provincial health department, said nine of those killed were men, while one victim was a child of four.
Officials suspect other cases may have gone undetected. Dr Mallick said hospitals were now being “vigilant”.
The ministry was “very concerned” about the amoeba, he said.
Cities on alert Although the amoeba is usually picked up in contaminated pools or lakes, only one of those killed had been swimming.
Officials are therefore concentrating their attention on the possibility that people picked it up when cleaning out their nostrils – a practice which is common in South Asia, BBC regional analyst Jill McGivering says.
The amoeba travels to the brain through the nasal passages.
Those infected have symptoms including fever, nausea and vomiting, as well as a stiff neck and headaches. Most die within a week.
The World Health Authority’s Musa Khan says other cities across Pakistan have been put on alert.
An awareness campaign has also been launched among health workers and the public.
“People should avoid getting water too deep into their nostrils,” Mr Khan said. “Those with symptoms should seek help immediately.”
People are being advised to use boiled or chlorinated water to rinse their noses, and to clean out domestic water tanks where amoeba may flourish.
The amoeba cannot be passed from person to person. 
Someone is trying to be funny by trying to poison my flat’s water tanks but it will never work, because the amoeba does not survive in room temperature, it will die within minutes.
– Contributed by Oogle.

Crisis, what crisis? Just watch for Inflation due to the expansion of credit

By Hugo Dixon

October 8, 2012

The credit crisis burst into the open five years ago. The euro crisis has been rumbling for over two years. The term “crisis” isn’t just on everybody’s lips in finance. Wherever one turns – politics, business, medicine, ecology, psychology, in fact virtually every field of human activity – people talk about crises. But what are they, how do they develop and what can people do to change their course?
The first thing to say is that a crisis is not just a bad situation. When the word is used that way, it is devalued. The etymology is from the ancient Greek: krisis, or judgment. The Greek Orthodox Church uses the term when it talks about the Final Judgment – when sinners go to hell but the virtuous end up in heaven. The Chinese have a similar concept: the characters for crisis represent danger and opportunity.
A crisis is a point when people have to make rapid choices under extreme pressure, normally after something unhealthy has been exposed in a system. To use two other Greek words, one path can lead to chaos; another to catharsis or purification.
A crisis is certainly a test of character. It can be scary. Think of wars; environmental disasters that destroy civilisations of the sort charted in Jared Diamond’s book Collapse; mass unemployment; or individual depression that triggers suicide.
But the outcome can also be beneficial. This applies whether one is managing the aftermath of Lehman Brothers’ bankruptcy, the current euro crisis, the blow-up of an oil rig in the Gulf of Mexico or an individual’s mid-life crisis. Much depends on how the protagonists act.
Students of crises are fond of dividing them into phases. For example, Charles Kindleberger’s Manias, Panics, and Crashes identifies five phases of a financial crisis: an exogenous, normally positive, shock to the system; a bubble when people exaggerate the benefits of that shock; distress when some financiers realise that the game cannot last; the crash; and finally a depression.
While there is much to commend in Kindleberger’s system, it is too rigid to account for all crises in all fields. It also downplays the possibility that decision-makers can change the course of a crisis. A more flexible scheme that leaves space for human agency to affect how events turn out has two just phases: the bubble and the crash.
The bubble is typically characterised by mania and denial. Things are going well – or, at least, appear to be. Feedback loops end up magnifying confidence. In corporations or politics, bosses surround themselves with lackeys who tell them how brilliant they are. In finance, leverage plays a big part.
This is not healthy. Manic individuals don’t know their limitations and end up taking excessive risks – whether on a personal level or in managing an organisation or an entire economy. As the ancient Greeks said, hubris comes before nemesis.
But before that, there is denial. People do not wish to recognise that there is a fundamental sickness in a system, especially when they are doing so well. For example, back in 2007 at the World Economic Forum in Davos, the greed was palpable. Market participants had such a strong interest in keeping the game going that they turned a blind eye to the unsustainable buildup of leverage.
The ethical imperative in this phase is to burst the bubble before it gets too big. That, in turn, means both being able to spot a bubble and having the courage to stop the party before it gets out of hand. Neither is easy. It’s hard to recognise a sickness given that there is usually some ideology which explains away the mania as a new normal. The few naysayers can be ridiculed by those who benefit from the continuation of the status quo.
What’s more, politicians, business leaders and investors rarely have long-term horizons. So even if they have an inkling that things aren’t sustainable, they may still have an incentive to prolong the bubble.
The crash, by contrast, is characterised by panic and scapegoating. People fear that the system could collapse. Negative feedback loops are in operation: the loss of confidence breeds further losses in confidence. This is apparent on an individual level as much as a macro one.
Events move extremely fast and decisions have to be taken rapidly. Witness the succession of weekend crisis meetings after Lehman went bust – or the endless euro crisis summits. The key challenge is to take effective decisions that avoid vicious spirals while not embracing short-term fixes that fail to address the fundamental issues. With the euro crisis:, for example, it is important to improve competitiveness with structural reforms not just rely on liquidity injections from the European Central Bank.
In this phase, there is no denial that there is a problem. But there is often no agreement over what has gone wrong. Protagonists are reluctant to accept their share of responsibility but, instead, seek to blame others. Such scapegoating, though, prevents people from reforming a system fundamentally so that similar crises don’t recur.
Crises will always be a feature of life. The best that humanity can do is to make sure it doesn’t repeat the same ones. And the main way to evolve – both during a bubble and after a crash – is to strive to be honest about what is sick in a system. That way, crises won’t go to waste.
Everybody can screw around all they want but they can never overcome the system that is in place for the IMF/World Bank where countries who refuse to contribute and expect money in return will not get anything until everybody agrees to get rid of nuclear weapons, where even the entire debt of the US can be written off if they give up big brother position to fix their own economy without meddling in UN politics and the Internet.
– Contributed by Oogle.

You need the breakdown of beta amyloid DNA to complete the picture, where it is possible to stop memory loss

Eli Lilly & Co. (LLY)’s experimental Alzheimer’s treatment slowed memory loss and cognitive decline in early-stage patients by about 30 percent, offering the first evidence that a medication may hamper the course of the ailment, researchers said.
The benefit, though small, supports further research targeting a protein called beta amyloid, said Rachelle Doody, chairwoman of Alzheimer’s disease research at Baylor College of Medicine who presented the findings today at the American Neurological Association meeting in Boston.
San Diego, supported Lilly’s report in August. At that time, Lilly said the drug, solanezumab, slowed mental decline in those with mild Alzheimer’s while providing no benefit to more advanced patients. To market the drug, Lilly may need to do another study to confirm the findings, said Maria Carrillo, a vice president of medical and scientific relations at the Alzheimer’s Association.
“This isn’t the home run that is going to get you a medication by the end of the year, but it is very encouraging because with subsequent studies this could be a viable therapeutic option,” Carrillo said in an interview. “We need more options for our patients and families. We are very encouraged by what this could mean.”

Next Steps

Lilly hasn’t met with the U.S. Food and Drug Administrationto discuss the next steps for gaining approval of the drug, said Eric Siemers, a senior medical director at Indianapolis-based Lilly.
The improvement may not be enough for regulatory clearance, according to Alex Arfaei, an analyst with BMO Capital Markets in New York.
“We continue to believe the absolute difference is only nominally statistically significant and indicative of a ’hint of clinical activity,’ but not clinically meaningful, and most likely not enough to warrant approval,” Arfaei wrote in a note today.
Lilly rose 5.3 percent to $50.78 at the close of trading in New York, the company’s biggest single-day gain since March 2009, and highest level since April 2008. Shares of Lilly have increased 22 percent this year.
About 5.4 million Americans have Alzheimer’s, the most- common form of dementia, and the number is expected to surge to as many as 16 million by 2050 as the population ages, according to the Alzheimer’s Association. Drugs on the market now address only the symptoms, not the underlying cause, and none has been shown to slow progression of the disease.
Solanezumab attaches to a protein called beta amyloid that builds up into clumps in the brains of Alzheimer’s patients. Lilly’s treatment is designed to prevent those clumps from forming.

Beta Amyloid

Whether preventing the buildup of beta amyloid will have an effect on patients has been debated for years by Alzheimer’s researchers. Pfizer Inc. (PFE) and Johnson & Johnson (JNJ) stopped late- stage testing of a drug that also targeted beta amyloid after it failed to show a benefit to patients. The medicine appeared to lessen a measure of nerve cell damage in the brain and the buildup of amyloid plaque, signaling it could show promise for early use.
Today’s findings add evidence to the argument that targeting beta amyloid provides a benefit to patients and should be tested further, Doody said.
The only other therapy in final-stage testing is Baxter International Inc. (BAX)’s Gammagard. The product is an expensive, scarce treatment derived from donated blood plasma that replaces antibodies in people whose immune systems can’t protect them from infection. Results on whether it could slow or stop Alzheimer’s may be available next year.
Lilly tested its drug in two studies involving a total of 2,000 patients, about two-thirds of whom had the mild form of the disease. Most patients in the studies were also taking one of the drugs currently on the market to treat the Alzheimer’s symptoms, such as Forest Laboratories Inc. (FRX)’s Namenda.

Two Studies

In the first study, called EXPEDITION 1, patients with mild Alzheimer’s had a 42 percent reduction in cognitive decline at 18 months, Lilly said today in a statement. In the second study, dubbed EXPEDITION 2, there was just a 20 percent reduction. When the mild patients from both studies were pooled together, Lilly said they found a 34 percent reduction in cognitive decline. Doody said researchers typically look for a 25 percent reduction when designing studies.
In one study, the treatment showed an improvement in daily activity functioning in patients with mild Alzheimer’s, though that benefit wasn’t statistically significant in the second study, Doody said.
None of the studies showed any benefit in the patients with the moderate stage of the disease.
To contact the reporter on this story: Shannon Pettypiece in New York at
To contact the editor responsible for this story: Reg Gale at

HFT : Is faster than a nanosecond fast enough?

1st problem, HFT cannot handle huge volume where the risks are not covered. There will huge garbage of unmatched orders which will freeze the exchange. By the time you match the orders, you would have lost money for a huge volatile market where there is no direction. No one has the knowledge or strategy to correct this issue in america now. The present strategy of all HFT programs is to drive the markets up or down thru volume by ticks will make the situation worse.Solution: Funneling devices will not work for gateways, you need an ultra wide gateway where each channel is able handle all the requests of a typical user, and there will be hundreds and thousands of users, so you need to scale up everything. Not only that you must be able to monitor all your threads to ensure completion of processes so if there is error able to loop and retry, with the ability to lock your threads and spread out your threads into individual channels. Nobody has developed this technology yet. Lastly all computer OS cannot multitask on multicore computers properly yet because of the problems I mentioned. Locking the thread, use BitLocker technology with modifications.